AT7687

1. AT7687 has no effect on body weight in humans.

   “There were no significant changes in weight at Day 29.”

   Human trialMAD part, Day 29Day 29

   First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

1. AT7687 decreases resting heart rate in humans (up to 5.3 bpm reduction).

   “up to 5.3 bpm reduction in resting heart rate at Day 22”

   Human trialMAD part, Day 22Day 22

   First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

More on Resting heart rate

1. AT7687 decreases LDL cholesterol in humans (up to -9.1%).

   “placebo-adjusted mean change in LDL-C was up to -9.1% at Day 29”

   Human trialMAD part, Day 29Day 29

   First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

More on LDL cholesterol

1. AT7687 decreases Insulinogenic Index in humans (SAD p=0.009, MAD p=0.029).

   “AT led to statistically significant change in post- minus pre-dose Insulinogenic Index in both SAD (p=0.009) and MAD (p=0.029)”

   Human trialSAD and MAD cohortsup to Day 29

   First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

More on Insulinogenic Index